by rvvadmin | Aug 19, 2022 | 2022
Notice of Annual and Special Meeting Of Shareholders Notice of Meeting and Management Information Circular for the Annual And Special Meeting of Shareholders to be held on September 19, 2022 Form of Proxy Voting Instruction Form Request for Financial Statements Email...
by rvvadmin | Aug 16, 2022 | 2022
TORONTO, Aug. 16, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...
by rvvadmin | Jul 25, 2022 | 2022
TORONTO, July 25, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased...
by rvvadmin | Jun 24, 2022 | 2022
FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, June 24, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a...
by rvvadmin | Jun 6, 2022 | 2022
The Company submits Data Access Plan to the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, June 06, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
